mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells

This is a combination therapy regimen consisting of three components: - **Mitoxantrone hydrochloride liposome injection** is a liposomal formulation of the anthracenedione chemotherapeutic agent mitoxantrone, which intercalates into DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and repair. The liposomal formulation may enhance delivery to tumor sites and reduce systemic toxicity. - **Fludarabine** is a purine analog antimetabolite that interferes with DNA synthesis by inhibiting DNA polymerase, ribonucleotide reductase, and DNA primase, resulting in cytotoxicity primarily in lymphocytes. - **CD19 CAR-T cells** are autologous T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell surface antigen CD19. These modified T cells recognize and kill CD19-expressing malignant B-cells through MHC-independent mechanisms involving direct cytotoxicity. This combination regimen is being investigated as a bridging therapy prior to or in conjunction with CD19-targeted CAR-T cell therapy for patients with acute lymphoblastic leukemia (ALL) or other B-cell malignancies. The goal is to improve disease control before or during the administration of CAR-T cell therapy[1][6][8].